Pfizer (PFE) Expected to Announce Quarterly Earnings on Tuesday

Pfizer (NYSE:PFE) is anticipated to post its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect Pfizer to post earnings of $0.79 per share and revenue of $16.9431 billion for the quarter. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS.Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 10:00 AM ET.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the business posted $0.60 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. On average, analysts expect Pfizer to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pfizer Stock Up 1.6%

Shares of NYSE:PFE opened at $24.68 on Friday. The stock has a market capitalization of $140.29 billion, a P/E ratio of 13.13, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The stock’s 50-day moving average price is $24.77 and its 200-day moving average price is $24.28. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer has a 12-month low of $20.92 and a 12-month high of $28.64.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Institutional Trading of Pfizer

Several large investors have recently bought and sold shares of the company. Darwin Wealth Management LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $32,000. WFA of San Diego LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $40,000. WealthCollab LLC grew its position in shares of Pfizer by 12.5% in the 2nd quarter. WealthCollab LLC now owns 3,985 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 442 shares during the period. Binnacle Investments Inc increased its stake in shares of Pfizer by 65.1% in the 2nd quarter. Binnacle Investments Inc now owns 5,752 shares of the biopharmaceutical company’s stock worth $139,000 after acquiring an additional 2,267 shares in the last quarter. Finally, State of Wyoming lifted its position in Pfizer by 77.8% during the 2nd quarter. State of Wyoming now owns 7,427 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 3,251 shares during the period. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on PFE shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a report on Friday. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.24.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.